<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Treatments for the purposes of curing or more effectively managing <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) are evolving </plain></SENT>
<SENT sid="1" pm="."><plain>Our study focused on patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with synchronous distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, and we analyzed the factors influencing patient survival </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Data review was conducted retrospectively </plain></SENT>
<SENT sid="3" pm="."><plain>Clinicopathological parameters included age, sex, site of primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell differentiation, number of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, presence of extrahepatic <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, treatment of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, pre-treatment carcinoembryonic antigen (CEA) level, status of treatment response, salvage treatment and survival </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 420 patients were identified and considered for our study </plain></SENT>
<SENT sid="5" pm="."><plain>Of those, 275 patients (65.4%) had liver-only <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, 100 patients (23.8%) had concomitant lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, and 40 patients (9.5%) had other <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, 145 patients (34.5%) had liver-directed treatment including surgical resection (28.5%), radiofrequency ablation (RFA) (10.6%) and transcatheter arterial chemoembolization (TAE) (1.2%) </plain></SENT>
<SENT sid="7" pm="."><plain>There were 80 patients (19%) with CEA levels &lt; 10, 135 patients (32.1%) with CEA 10-100, and 165 patients (39.2%) with CEA &gt; 100 </plain></SENT>
<SENT sid="8" pm="."><plain>There were 200 patients (47.6%) who had received chemotherapy, 130 patients (30.9%) with target therapy, and 40 patients (9.5%) who had not undergone any salvage treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Three significant factors were identified, including treatment of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (p=0.027), pre-treatment CEA (p=0.04), and salvage treatment (p=0.005) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: We demonstrated three factors influencing patient survival including treatment of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, pre-treatment CEA level, and salvage treatment </plain></SENT>
<SENT sid="11" pm="."><plain>Aggressive treatment of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> including surgical resection or RFA combined with chemotherapeutic agents appear to provide an increased rate of survival to patients </plain></SENT>
</text></document>